8-K: Scholar Rock's Apitegromab Achieves Positive Phase 3 Results in Spinal Muscular Atrophy Trial

Scholar Rock's apitegromab met its primary endpoint in a Phase 3 trial, showing statistically significant and clinically meaningful improvement in motor function for patients with spinal muscular atrophy.

Summary

• Scholar Rock announced positive topline results from its Phase 3 SAPPHIRE trial for apitegromab, a treatment for spinal muscular atrophy (SMA).
• The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in motor function as measured by the Hammersmith Functional Motor Scale Expanded (HFMSE).
• Patients receiving apitegromab showed a 1.8 point mean improvement in HFMSE compared to placebo in the main efficacy population (ages 2-12).
• Specifically, 30.4% of patients on apitegromab achieved a greater than 3-point improvement in HFMSE, compared to 12.5% on placebo.
• The study included 188 patients, with 156 in the main efficacy group (ages 2-12) and 32 in an exploratory group (ages 13-21).
• Apitegromab showed consistent benefits across all age groups (2-21) and demonstrated early motor function improvement compared to placebo from the first measured time point at 8 weeks.
• The safety profile of apitegromab was favorable and consistent with previous trials, with no new safety concerns identified.
• Scholar Rock plans to submit a U.S. Biologics License Application and a European Union marketing authorization application in the first quarter of 2025.

Sentiment

Score: 9

Explanation: The document presents very positive results from a Phase 3 trial, with clear statistical significance and clinical meaningfulness. The safety profile is also favorable, and the company is moving towards regulatory submissions. This is a very positive development for the company and its investors.

Positives

• The primary endpoint of the Phase 3 SAPPHIRE trial was met, demonstrating a statistically significant and clinically meaningful improvement in motor function.
• Apitegromab showed consistent benefits across all age groups (2-21).
• The treatment was well-tolerated with a favorable safety profile.
• 98% of SAPPHIRE patients enrolled in the ongoing ONYX open-label extension study.
• Apitegromab demonstrated early motor function improvement compared to placebo from the first measured time point at 8 weeks.
• The study showed a 1.8 point mean improvement in HFMSE for the combined dose of apitegromab compared to placebo.
• 30.4% of patients receiving apitegromab achieved a greater than 3-point improvement in HFMSE compared to 12.5% on placebo.

Negatives

• The 20 mg/kg dose of apitegromab did not achieve statistical significance on its own, with a mean difference of 1.4 points compared to placebo (p=0.1149).
• Some patients experienced adverse events, although these were consistent with the underlying disease and standard of care.

Risks

• The full results from the Phase 3 SAPPHIRE trial may differ from the topline data.
• Regulatory approval is not guaranteed, and the FDA or EMA may require additional data.
• Competition from other companies developing treatments for SMA could impact market share.
• The company's ability to manage expenses and obtain additional funding is crucial for continued development and commercialization.
• The company is dependent on third parties for the development and manufacture of the drug.

Future Outlook

Scholar Rock plans to submit regulatory applications in the U.S. and Europe in Q1 2025, with a potential U.S. launch in Q4 2025 and a European launch to follow. They also plan to initiate an under 2 study for SMA in mid-2025 and have an obesity trial readout expected in Q2 2025.

Management Comments

• Jay Backstrom, M.D., MPH, President and Chief Executive Officer of Scholar Rock, stated that the results clearly demonstrate robust and clinically meaningful improvement in motor function in patients with SMA.
• Jing Marantz, M.D., Ph.D., Chief Medical Officer at Scholar Rock, noted that the positive Phase 3 SAPPHIRE trial, along with over 4 years of TOPAZ clinical trial data, clearly demonstrate the potentially transformative benefit of apitegromab.
• Kenneth Hobby, President of Cure SMA, stated that these encouraging trial results mark a critical milestone for the SMA community.

Industry Context

This announcement is significant as it addresses a critical unmet need in SMA treatment by targeting muscle weakness directly, unlike existing therapies that primarily focus on motor neuron loss. The positive results position Scholar Rock as a potential leader in the SMA treatment landscape.

Comparison to Industry Standards

• The results of the SAPPHIRE trial show a 1.8 point improvement in HFMSE for the combined dose of apitegromab compared to placebo, which is a clinically meaningful improvement.
• Existing SMA therapies, such as nusinersen and risdiplam, primarily target motor neuron loss, while apitegromab directly addresses muscle atrophy, offering a different approach.
• The study's results are particularly notable as they show improvement in motor function, whereas studies of existing therapies have shown a slowing of decline.
• The 30.4% of patients achieving a 3-point improvement in HFMSE with apitegromab is a significant outcome compared to the 12.5% in the placebo group.
• The long-term safety data from the TOPAZ trial, with over 48 months of treatment experience, provides additional confidence in the safety profile of apitegromab.

Stakeholder Impact

• Shareholders are likely to react positively to the successful trial results and the potential for regulatory approval.
• Patients with SMA and their families will benefit from a new treatment option that has shown significant improvement in motor function.
• Employees of Scholar Rock will be motivated by the progress of their lead drug candidate.
• The positive results may attract new investors and partners to the company.

Next Steps

• Scholar Rock plans to submit a U.S. Biologics License Application and a European Union marketing authorization application in Q1 2025.
• The company will present detailed results at an upcoming medical conference in early 2025.
• They plan to request priority review (FDA) and accelerated assessment (EMA).
• A US launch is planned for Q4 2025 with a EU launch to follow.
• An under 2 study for SMA is planned for mid-2025.
• The EMBRAZE readout for obesity is expected in Q2 2025.

Key Dates

Keywords

apitegromab, spinal muscular atrophy, SMA, Phase 3 trial, motor function, HFMSE, biologics license application, marketing authorization application, myostatin, neuromuscular disease